Interestingly, we found a synergetic effect on suppressing tumor progression, as well as extending survival, by a combination administration of DKK2 blockade with a suboptimal dose of anti-VEGFR via activation of CD8+ T/NK cells and impaired tumor angiogenesis. The gene discussed is KDR; the disease is neoplasm.